Understanding how specific genetic variants affect kidney disease risk in African Americans
APOL1 Nephropathy: Linking Genetics and Mechanisms
['FUNDING_R01'] · BETH ISRAEL DEACONESS MEDICAL CENTER · NIH-10752626
This study is looking at how certain genetic changes in the APOL1 gene can raise the risk of kidney disease in African Americans, and it aims to understand how these changes affect kidney health, which could help find new ways to prevent or treat kidney problems.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BETH ISRAEL DEACONESS MEDICAL CENTER (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10752626 on ClinicalTrials.gov |
What this research studies
This research investigates the role of genetic variants in the APOL1 gene that significantly increase the risk of kidney disease among African Americans. By studying these variants, the research aims to uncover the mechanisms behind kidney failure, particularly focusing on how the presence of two specific APOL1 variants leads to increased toxicity in kidney cells. The approach includes using advanced genetic engineering techniques in animal models to explore how these variants interact and affect kidney function. This could provide insights into potential therapeutic strategies to mitigate the risks associated with these genetic factors.
Who could benefit from this research
Good fit: Ideal candidates for this research are African Americans who carry two APOL1 risk variants and are at a higher risk for kidney disease.
Not a fit: Patients who do not have the APOL1 risk variants or those with kidney disease from other causes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved prevention and treatment strategies for kidney disease in individuals with high-risk genetic profiles.
How similar studies have performed: Previous research has shown promising results in understanding genetic contributions to kidney disease, making this approach both relevant and potentially impactful.
Where this research is happening
BOSTON, UNITED STATES
- BETH ISRAEL DEACONESS MEDICAL CENTER — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FRIEDMAN, DAVID J — BETH ISRAEL DEACONESS MEDICAL CENTER
- Study coordinator: FRIEDMAN, DAVID J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.